Skip to main content

Table 6 Univariate analysis for risk factors for early death (within 90 days after treatment initiation)

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Variable

Univariate analysis

N

OR

[95% CI]

p-value

Age (years)

 < 65

11/61

1.00

  

 ≥65

17/68

1.52

[0.65–3.56]

0.34

Sex

 Male

17/68

1.00

  

 Female

11/61

0.66

[0.28–1.55]

0.34

ECOG PS

 0–1

13/77

1.00

  

 2–4

15/52

2.00

[0.86–4.65]

0.11

Disease status

 Advanced

28/120

NC

 

NC

 Recurrent

0/9

Primary site

 Stomach

26/123

1.00

  

 GEJ (vs. stomach)

2/6

1.87

[0.32–10.76]

0.49

No. of metastatic sites

 1–2

19/100

1.00

  

 ≥3

9/29

1.92

[0.76–4.87]

0.17

Subtype of SPM

 Massive ascites

16/62

1.00

  

 Inadequate oral intake

7/35

0.72

[0.26–1.96]

0.52

 Both

5/32

0.53

[0.18–1.62]

0.27

Serum albumin level

> 3.1 g/ml

10/68

1.00

  

 < 3.1 g/ml

18/61

2.43

[1.02–5.78]

0.05

Serum CRP level

 < 2.2 mg/dl

8/62

1.00

  

> 2.2 mg/dl

20/67

2.87

[1.16–7.13]

0.02

  1. CI confidence interval, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, NC not calculated, OR odds ratio, SPM severe peritoneal metastasis